PRTN3 and kidney failure: In contrast, there were no significant differences between eGFR at diagnosis, 6 months postdiagnosis, and 12 months postdiagnosis in PR3-ANCA seropositive participants who have severely reduced kidney function or kidney failure (KDIGO stages 4–5) at diagnosis.